



Behavioral Health is Essential To Health



Prevention Works





Treatment is Effective



People Recover







Prescription Drug Abuse & Misuse: Neurobiology, Epidemiology, & EBPs

H. Westley Clark, M.D., J.D., M.P.H., CAS, FASAM

Director

Center for Substance Abuse Treatment Substance Abuse Mental Health Services Administration U.S. Department of Health & Human Services

ASTHO Winter Member Meeting Prescription Drug Abuse & Misuse Chapel Hill, NC• December 4, 2013







President Barack Obama

"Every day, millions of Americans with substance use disorders commit to managing their health by maintaining their recovery from drug or alcohol addiction. People in recovery are not strangers: they are our family members, friends, colleagues, and neighbors. "

Presidential Proclamation -- National Alcohol and Drug Addiction Recovery Month, 2012



Secretary Kathleen Sebelius
U.S. Department of Health & Human Services

"We have a very real opportunity to improve – and in some cases save the lives of millions of our friends, neighbors and family members. We have to change hearts in order to treat minds."


> Carter Center, November 8, 2013

Behavioral Health + Physical Health = Whole Health



- → BH & PH are interdependent, and whole health depends on both.
- → Prevention, treatment, and recovery are essential for behavioral *and* physical health.

Prescription Drugs Abuse & Misuse: Public Awareness & Policy Initiatives









hs. Do not dispense u

Mallinckrodt

F.D.A. Urging a Tighter Rein on Painkillers

Prescription Drug Abuse & Misuse: Strategies to Stop the Epidemic








SAMHSA's Strategic Initiatives & Partnerships


Topics

- → Neurobiology
- → Epidemiology
- → EB Treatment
- → Fostering EBPs



Topics

- → Neurobiology
- → Epidemiology
- → EB Treatment
- → Fostering EBPs




Addiction is a Chronic Brain Disease


- → Drug and alcohol addiction are chronic & relapsing diseases involving the brain's reward and control circuitries.
- → Neuroadaptations that follow chronic drug exposure ultimately serve to impair the function of brain regions involved with motivation and self-control.
- → Substance dependence disorders have relapse rates similar to those of hypertension, diabetes, and asthma.

Addiction is like other chronic diseases...


- →It changes biology
- → It is preventable
- → It is treatable
















Endogenous Reward Pathway: Example



Dopamine & Exogenous Opioids: Hypercharging the Brain Reward Pathway

- → Nearly all drugs of abuse increase dopamine neurotransmission, and in doing so increase activity in the brain reward pathway.
 - Many of these drugs activate the brain reward pathway more effectively – and for longer periods of time – than endogenous molecules, and consequently have an intrinsic risk of abuse.




Other Neurotransmitter Systems


- → Scientific research has shown that other neurotransmitter systems are also affected:
 - Serotonin: Regulates mood, sleep, etc.
 - Glutamate: Regulates learning and memory, etc.

Dopamine Pathways

Serotonin Pathways



Opioid Binding Sites




Prolonged Drug Use

- → Changes the brain in fundamental ways that reinforce drug taking and lead to addiction.
 - Structural & functional changes
 - Can impair mental & motor functions (e.g., memory deficits, slowed motor reactions)
- → Changes are difficult to un-do and may be long lasting.
- → Successful prevention efforts & early intervention are key to avoid/mitigate these neural changes.

One Size Does Not Fit All: Addiction

- → Addiction involves the complex interaction of multiple, individual-specific factors including a person's inherent biology as well as their environment, experience, and age.
 - Gene-environment interactions
 - Developmental stages
 - Mental health & stressful life events including physical & sexual abuse
 - Evidence that social factors and life experiences influence dopamine transmission pathway
 - Co-morbidities


Addiction: Neurobiological Interdependencies




→ All of these brain regions must be considered in developing strategies to effectively treat addiction.

Topics

- → Neurobiology
- → Epidemiology
- **→**Treatment
- → Fostering EBPs




Specific Illicit Drug Dependence or Abuse in the Past Year among Persons >12 years old




Numbers in Thousands


SAMHSA NSDUH 2013 25

Past Month Nonmedical Use of Types of Psychotherapeutic Drugs among Persons >12 years old



Past Year Nonmedical Pain Reliever Use among Youths and Young Adults in NSDUH and MTF






MTF = Monitoring the Future; NSDUH = National Survey on Drug Use and Health.

Note: Data for MTF are for "narcotics other than heroin."


⁺ Difference between this estimate and the 2012 estimate is statistically significant at the .05 level.

Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users



¹ The Other category includes the sources "Wrote Fake Prescription," "Stole from Doctor's Office/Clinic/Hospital/Pharmacy," and "Some Other Way."


Past Month Nonmedical Use of Types of Psychotherapeutic Drugs among Persons >12 years old



Past Month and Past Year Heroin Use among Persons >12 years old




First Specific Drug Associated with Initiation of Illicit Drug Use among Past Year Illicit Drug Initiates >12



2.9 Million Initiates of Illicit Drugs


Note: The percentages do not add to 100 percent due to rounding or because a small number of respondents initiated multiple drugs on the same day. The first specific drug refers to the one that was used on the occasion of first-time use of any illicit drug.

Past Year Initiates of Specific Illicit Drugs among Persons > 12 years old




Note: Numbers refer to persons who used a specific drug for the first time in the past year, regardless of whether initiation of other drug use occurred prior to the past year.

Mean Age at First Use for Specific Illicit Drugs among Past Year Initiates Aged 12 to 49



SAMHSA NSDUH 2013

Substances for Which Most Recent Treatment Was Received in the Past Year among Persons > 12 years old




Numbers in Thousands

SAMHSA NSDUH 2013


Percentage of ED visits involving nonmedical use of pharmaceuticals

Total ED visits in 2011 = 1,244,872



Percentage of ED visits involving nonmedical use of pharmaceuticals


Total ED visits in 2011 = 1,244,872



SAMHSA DAWN 2013

Percentage of ED visits involving nonmedical use of pharmaceuticals

Total ED visits in 2011 = 1,244,872




SAMHSA DAWN 2013 Age

Opioid Related Emergency Department Visits

- → Large increase in the number of ED visits involving nonmedical use of pharmaceuticals observed between 2004 and 2011.
 - Percentage change for opioid involved visits =183% increase.
 - –Oxycodone had the largest impact = 263% increase.
- → Short term trend: 15% increase from 2009-2011.
- → Pain relievers were involved in 38.0 % of drug-related suicide attempts.
 - Narcotic pain relievers were involved in over a third of that number (13.9%).

Primary Opiates*/Synthetics Admissions 2000-2010 (Per 100,000 >12 years old; *non-heroin)




Incomplete data

- → Rate for opiates was 400 percent higher in 2010 than in 2000.
- → Rates increased in every year from 2000 through 2010.

Topics

- → Neurobiology
- → Epidemiology
- → EB Treatment
- → Fostering EBPs




EBP: Recovery Oriented Systems of Care (ROSC)

Treating a Chronic Disorder Must Treat the <u>Whole</u> Person in Their Social Context

Pharmacological Treatments (Medications)

Medical Services



ROSC: A Way to Better Health for All

- → Recovery complements prevention and treatment services in behavioral *and* physical medicine.
- → Recovery focuses on an individual's strengths; on social engagement; on wellness; and on holistic health.
- → Recovery looks forward; and while it learns lessons from the past, it does not use the past as a metric for the present or as a prognosis for the future.
- → Recovery does not look at a person and see a disease; but looks at an individual and sees a way to better health for the person, their family, and their community.



ROSC Framework

- →Provides a coordinated network of community-based services and supports that is person-centered.
- → Builds on the strengths and resilience of individuals, families, and communities to achieve abstinence and improved health, wellness, and quality of life for those with or at risk of alcohol and drug problems.

ROSC Values

- → Evidence-based
- → Person-centered
- → Self-directed
- → Strength-based
- →Participation of family members, caregivers, significant others, friends, and the community
- →Individualized and comprehensive services and supports
- → Community-based services and supports

One Size Does Not Fit All: Evidence-Based Treatments

- → Just as individuals vary in their susceptibility to chronic diseases, individuals vary in their response to treatments.
- → This is true for <u>all chronic diseases</u> including addiction:
 - For some, behavioral interventions may be effective & sufficient
 - For others, behavioral interventions may need to occur in conjunction with medication
 - Different medications may be more effective
 & appropriate for different individuals

Evidence-based Treatments for Addictions

- Medical Detoxification
- Outpatient Psychoeducation
- Outpatient Relapse Prevention
- Residential Therapeutic Treatment
- Family Therapy
- Self-Help Support Systems
 - 12 Step Programs (e.g., AA, NA, CA, MA)
 - Rational Recovery or Secular Organizations for Sobriety (SOS)
- Toxicology Screens/abstinence monitoring
- Medication Assisted Treatment (MAT)

Medication <u>Assisted</u> Treatment

- → MAT is not a stand-alone treatment choice:
 - It is part of an overall EB treatment program that includes behavioral, cognitive, & other recoveryoriented interventions.
 - This overall EB treatment may include medication where it is determined to be medically necessary and appropriate.
- →MAT, in principal, is used widely to treat a number of chronic diseases including heart disease and diabetes.

48

Medication Assisted Treatment (cont.)

- → Individuals have varied responses to different medications
 - including medications used to treat heart disease *and* to treat people at risk for heart disease.
 - Effectiveness of medications vary among individuals
 - Side effects vary among individuals
 - Adherence constraints also vary by individual, and for a given individual these constraints may vary over time/personal circumstance
- → These individual-specific responses to medications hold true for treatment of addictions.

EBP: Rehabilitation & Therapeutic MAT for Opioid Addiction

- → Naltrexone can be used as an opioid blocker for those at risk for using opioids.
 - Vivitrol
- → Methadone and Buprenorphine can be used for opioid maintenance for those unable to remain opioid free.
- → Naloxone: Life-saving medication for opioid overdose.

EB Treatment is Complicated: Unintended Consequences

The New York Times HEALTH | Log in | Register Now | Help

Online November 16-17, 2013

THE DOUBLE-EDGED DRUG

Addiction Treatment With a Dark Side

In Demand in Clinics and on the Street, 'Bupe' Can Be a Savior or a Menace



At Clinics, Tumultuous Lives and Turbulent Care




EB Treatment is Complicated: Interdependencies



Topics

- → Neurobiology
- → Epidemiology
- →EB Treatment
- → Fostering EBPs



EBP Opioid Overdose Toolkit

SAMHSA Opioid Overdose TOOLKIT

Over 23,000 downloads*



- → Educate individuals, families, first responders, prescribing providers, and community members.
- → Practical, plain language information about steps to take to prevent opioid overdose and to treat overdoses (including the use of naloxone).
- → 5 modules, each one customized to address the specific needs of target audiences.
- → Important resources for patients, families, prescribers, and communities. 54

*August 27-October 31 2013


EBP Technical Assistance & Workforce Development



- → SAMHSA's ATTC Network
 - EBP Technical assistance
 & technology transfer
 - Workforce Development
 - Training
 - Distance education
 - Research translation
 - Resource dissemination

EBP Treatment Protocols and KAP Keys





http://162.99.3.213/products/manuals/tips/pdf/TIP43.pdf http://162.99.3.213/products/tools/keys/pdfs/KK 43.pdf

EBP Opioid Treatment Guidelines

Federal Guidelines for Opioid Treatment

April 2013


EBP Consensus Guidelines (in process): The use of extended-release injectable naltrexone.


- → Target audience is non-addictions specialist prescribers.
- →Goal is to increase adoption of these evidence based practices.
- → Correctional facilities can use this as a foundation for adding extended-release injectable naltrexone to their array of treatment options.

EBP Guidelines (in process) for Treatment of Opioid Dependent Pregnant and Parenting Women

- →SAMHSA is convening two panels of experts and will use the Rand UCLA appropriateness method to establish best available medical and clinical practice to optimize outcomes for this population.
- → Development and dissemination will be accomplished with collaboration across SAMHSA centers.

EBP Literature Reviews





http://captus.samhsa.gov/prevention-practice/targeted-prevention/prescription-drug-abuse

EBP: Screening, Brief Intervention & Referral to Treatment (SBIRT)

- →Embedding screening, brief intervention, referral & treatment of substance abuse problems within primary care settings such as emergency centers, community health care clinics, and trauma centers helps to:
 - Identify patients who don't perceive a need for treatment,
 - Provide them with a solid strategy to reduce or eliminate substance abuse, and
 - Move them into appropriate services.

EBP: SBIRT's Return-on-Investment

SAMHSA's 2012 SBIRT: Clients served = 133,043

Clients reporting No Alcohol/Drug Use	At Intake	6-Month Follow-up	Difference
Brief Intervention	8%	40%	企 398%
Brief Treatment	8%	40%	企 400%
Referral to Treatment	6%	42%	 1 600 %

SAMHSA SAIS 2013

EBP: SAMHSA's Block Grants

- → Emphasis on EBPs.
- →Inherent flexibility allows each state/locality to support EBPs that address the unique needs of their citizenry, including prescription drug abuse & misuse.
- →In response to dynamic shifts in MH/SUD needs, like the Rx drug problem, BG funds may be repurposed & realigned to better meet these needs.

SAMHSA Block Grants (Dollars in Thousands)

			FY2014
		FY2013	President's
	FY2012 Actual	Annualized CR	Budget
SABG	\$1,800,332	\$1,811,350	\$1,819,856

\$462,570

SABG: Substance Abuse Prevention and Treatment Block Grant

MHBG: Community Mental Health Services Block Grant

\$459,756

MHBG

SAMHSA FY2014 CJ; Dollars in thousands CR in effect until January 15, 2014. (Public Law No: 113-46; www.thomas.gov)

\$459,756

EBP: National Action Plan for PDMPs



Implementation of National Action Plan for PDMPs (Phases 1&2)

- → SAMHSA provided funding for implementation of the Action Plan through the "Enhancing Access to PDMPs through Health IT Project".
 - SAMHSA partnered with ONC, ONDCP, & the CDC.
 - ONC has management oversight of the effort.

Implementation of the National Action Plan: SAMHSA's PDMP HIT Grants

- →Improve real-time access to PDMP via existing technologies like EHRs (FY12,13).
- →Strengthen operational state of PDMPs by increasing interoperability between states (FY12).
- → Evaluate the impact of the enhancements on Rx drug abuse (FY12).
 - FY 12: 2 year funding for 9 states (FL, IL, IN, KS, ME, OH, TX, WA, WV)
 - FY 13: 2 year funding for 7 states (KY, MA, ND, NY, RI, SC, WI)

Key Takeaways of National Action Plan for PDMPs (Phases 1&2)

- →Integrating into provider workflow reduces barriers to PDMP access and increases utilization.
- → Type of integration can vary:
 - Value increases with degree of automation;
 - But even basic integration (hyperlink to PDMP, return PDF) is valued.
- → When available, the PDMP is valuable as a clinical decision support tool.
- → Phase 3 just launched.

Closing Thought: First, do no harm...

"Advancing Access to Addiction Medications"

→ This 2013 ASAM-commissioned report found that Medicaid agencies in only 28 states cover all 3 FDA approved medications; and that private insurers & Medicaid state agencies often impose rigid, scientifically indefensible limitations on medically necessary substance abuse treatment.

"Advancing Access to Addiction Medications"

- → As PEW noted in its coverage of this report:
 - "You wouldn't deprive a diabetic of insulin", and you "wouldn't hold back a statin from a patient with high cholesterol."
 - While we are working to reduce prescription drug misuse, abuse, & diversion, we must ensure that people with a legitimate medical need for these drugs can afford them and can access them without barriers, impediments, or constraints.

THANK YOU!

Westley.Clark@samhsa.hhs.gov